Babcock, Michael C.
Mikulka, Christina R.
Wang, Bing
Chandriani, Sanjay
Chandra, Sundeep
Xu, Yue
Webster, Katherine
Feng, Ying
Nelvagal, Hemanth R.
Giaramita, Alex
Yip, Bryan K.
Lo, Melanie
Jiang, Xuntian
Chao, Qi
Woloszynek, Josh C.
Shen, Yuqiao
Bhagwat, Shripad
Sands, Mark S.
Crawford, Brett E.
Funding for this research was provided by:
BioMarin Pharmaceutical
National Institutes of Health (R01 NS100779)
Article History
Received: 26 April 2021
Accepted: 25 June 2021
First Online: 14 July 2021
Competing interests
: MCB, BW, SaC, SuC, YX, KW, YF, AG, BKY, ML, QC, JCW, YS, SB, and BEC are current or former employees of BioMarin which has filed patent applications on the CGT inhibitors, US Patent WO 2017/214505 Al and WO/2020/028221. All other authors declare they have no competing interests<b>.</b>